Search:
Home | Register or Login | Contact Us
 
  Treatment &
Prevention Home
  Prediabetic Conditions
  Type 1 Diabetes
  Type 2 Diabetes
  Pediatric Diabetes
  Gestational Diabetes
  Macrovascular Complications
  Microvascular Complications
Treatment Guidelines
  Emerging Therapies
 

Comparison of Human Insulins and Insulin Analogues

Insulin Preparation

Onset of Action

Peak Action

Duration of Action

Rapid-Acting

Humalog® (lispro)

Novolog® (aspart)

 

5-15 minutes

5-15 minutes

 

30-90 minutes

40-60 minutes

 

4-5 hours

3-5 hours

Short-Acting

Human regular

 

30-60 minutes

 

2-4 hours

 

6-10 hours

Intermediate-Acting

NPH/Lente

 

1-2 hours

 

4-8 hours

 

10-20 hours

Long-Acting

Ultralente

Glargine

 

2-4 hours

1-2 hours

 

8-20 hours

No peak

 

16-24 hours

24 hours

Data derived from Humalog prescribing information.[1] Data derived from Novolog prescribing information.[2] All other data from Abramowicz [3] and Rosenstock.[4]

References

  1. Eli Lilly. Humalog prescribing information.
  2. Novo Nordisk Pharmaceuticals, Inc. Novolog prescribing information.
  3. Abramowicz M. Drugs for diabetes. Medical Letter. 2002;1:1-6.
  4. Rosenstock J. Insulin therapy: optimizing control in type 1 and type 2 diabetes. Clin Cornerstone. 2001;4:50-64.
 



About Us | Terms of Use | Privacy Statement | Disclaimer